Indian physicians who were involved in the controversial "superbug" NDM-1 study that was published in Lancet Infectious Diseases last month have been asked to confirm whether they followed various national guidelines and procedures required.....

Index Ventures, the global high tech venture capitalist, has appointed Dr Kevin Johnson as a life sciences partner to enhance its push into developing asset-centric investment strategy. Dr Johnson, who was both a venture adviser and CEO of.....

Celator Pharmaceuticals has raised $20 million in a series D round led by new investor Thomas, McNerney & Partners. Alex Zisson, a partner at the venture capital firm, will join Celator's board.

Proceeds from the financing will.....

The US agency that runs Medicare – the Centers for Medicare and Medicaid Services (CMS) - has scheduled a 17 November advisory panel meeting to consider on-label and off-label use of Dendreon's prostate cancer treatment Provenge.....

Two Scottish university spin-out companies, ImmunoSolv and Grampian BioConsultants (GBC), have merged to combine their expertise in immunology and immuno-technology to avoid becoming a "one-trick pony".

The merged company, which is focused on.....

The small UK biotechnology firm Henderson Morley has filed a notice of intention to call in the administrators following its failure to secure the divestment of its ICVT (Ionic Contra Viral Therapy) portfolio to KMS Therapeutics, resulting.....

Addex has announced plans to move an mGluR2 antagonist into Phase I trials for Alzheimer's disease (AD) in around a year. "We are currently in late-stage optimisation, and plan to have a clinical candidate by the end of the year," Addex's.....